Company Enters Functional Beverages Market
with Plant-Based Water Products
MONTREAL, March 19, 2020 /CNW/ - Mondias Natural Products
Inc. (TSXV: NHP) (the "Company" or "Mondias")
specializing in evidence-based natural products for the healthcare,
bio-agriculture and functional beverages markets today announces
that the Company has entered into a Definitive Agreement on
March 17th, 2020 to
acquire substantially all assets of Érablier Inc. a premium maple
water products company from Québec, Canada. The addition of
Érablier, a Premium Plant-Based Water Beverages company will expand
Mondias' natural products-based portfolio and further deliver on
its vision to offer consumers healthy and nutritious
experiences.
![Logo: Mondias Natural Products (CNW Group/Mondias Natural Products Inc.) Logo: Mondias Natural Products (CNW Group/Mondias Natural Products Inc.)](https://mma.prnewswire.com/media/1135809/Mondias_Natural_Products_Inc__Mondias_Announces_Definitive_Agree.jpg)
The acquisition was valued at CAD $1,000,000. Mondias to pay an initial
consideration of $250,000 by issuing
1,666,667 shares*. Shares issued will be in escrow and
released at a rate of 20% for every $1,000,000 of net sales of Érablier
products. Additionally, a 4% royalty rate to be paid on net
sales of Érablier products for an additional consideration up to a
maximum of $750,000. An advanced
royalty payment of $68,500
(applicable to the $750,000 maximum
royalty) will be payable when the financial conditions would allow
it.
Mondias CEO Dr. Patrick Frankham
stated that "Érablier offers distinctive products that deliver the
great taste and natural ingredients consumers are looking
for." Dr Frankham added that "the opportunity to acquire a
unique ready-to-market beverage with natural ingredients, from the
largest source of plant-based water in North America is a great entry into the
competitive functional beverages market. The addition of Mr. Fleury
to our team with his prior experience with the successful launch of
Slow Cow, is an important milestone in building the functional
beverage franchise for our Company."
As part of the Agreement, Mr. Lino
Fleury will join Mondias as Brand Director for Érablier. Mr.
Fleury has extensive experience in the functional beverages market.
He was past inventor and founder of Slow Cow a successful natural
relaxation beverage having a mix of amino acids and a mixture of
known natural health products distributed internationally since
2008.
Érablier has developed a premium product made from the organic,
and pure processed water obtained from sugar maple tree sap
(acer saccharum). In maple syrup water industry reports,
data shows that the demand for maple water has grown to exceed
16M Liters in 2018. Consumers
who drink maple water, may enjoy the same experience as seen with
coconut water. According to an industry report, the global coconut
water market is valued at USD $2.5B
in 2017 and is expected to reach USD $9.0B by the end of 2024, growing at a CAGR of
19.93% between 2017 and 2024.
*: The issuance of shares is subject to TSX approval.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the healthcare,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries, commercial greenhouses and to indoor cannabis growers,
in collaboration with McGill's Faculty of Agricultural and
Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than statements of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by the use of the words
"may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include the Company's inability to obtain sufficient financing to
execute its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise except as required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.